Sumitomo Pharma America
55 Cambridge Parkway Suite 102W
Cambridge, MA 02142
United States
Tel: +1(508)481-6700
Website: https://www.us.sumitomo-pharma.com/
169 articles about Sumitomo Pharma America
-
Myovant Strengthens Management Team and Adds New Directors to the Board
11/7/2018
Kim Sablich, Chief Commercial Officer, and Jeff Nornhold, Senior Vice President, Pharmaceutical Operations & Development, join Myovant's Executive Committee
-
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
10/8/2018
Collaboration will focus initially on creating a feature in the Flo app to both enable women to monitor for heavy menstrual bleeding and enable research on digital biomarkers for heavy menstrual bleeding
-
Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018
8/7/2018
Completed patient screening for Phase 3 LIBERTY 1 Trial
-
Myovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Shares
7/13/2018
Myovant Sciences Ltd. announced the pricing of its underwritten public offering of 3,333,334 of its common shares at a price to the public of $22.50 per share.
-
Myovant Sciences Ltd. Announces $75 Million Public Offering of Common Shares
7/11/2018
Myovant Sciences Ltd. announced that it has commenced an underwritten public offering of $75 million of its common shares.
-
Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids
7/10/2018
Top-line data for LIBERTY 1 expected in second quarter of 2019
-
Myovant Sciences to Present at First Annual Roivant Pipeline Day
6/18/2018
Myovant Sciences announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the first annual Roivant Pipeline Day on July 10, 2018 at 2:30 p.m. ET.
-
Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018
6/7/2018
Myovant Sciences announced corporate updates and reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2018.
-
Not only does the company have to deal with the U.S. Food and Drug Administration’s three month PDUFA delay for elagolix, but now the watchdog organization, The Institute for Clinical and Economic Review (ICER), has released some disconcerting news over pricing.
-
AbbVie and Neurocrine Biosciences announced that its Phase III ELARIS UF-II trial of elagolix for uterine fibroids met its primary endpoint.
-
Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017
2/14/2018
Positive results in two Phase 3 clinical studies conducted by Takeda to evaluate the efficacy and safety of relugolix for the treatment of uterine fibroids.
-
7 Hot Biotech Investing Bets
12/20/2017
We now turn to six MoneyShow.com contributors for their best ideas in biotechnology, a sector with both high risk and the potential for high rewards. -
Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017
11/14/2017
R&D expenses for the quarter ended September 30, 2017 were$24.4M, compared to $3.8M for the comparable period in 2016.
-
Myovant Sciences Announces Positive Top-line Results From Takeda's Phase III Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated With Uterine Fibroids
11/9/2017
Relugolix met the primary endpoint with 57.6% of women achieving marked improvement in pain symptoms compared to 3.1% of women receiving placebo.
-
Ramaswamy's Myovant Sciences Scores $140M
10/16/2017
Myovant Sciences has secured up to $140 million in flexible financing commitments from NovaQuest Capital Management and Hercules Capital. -
Myovant Announces Positive Top-Line Results From Takeda's Phase III Study Evaluating The Efficacy And Safety Of Relugolix Compared With Leuprorelin For The Treatment Of Uterine Fibroids
10/3/2017
-
Myovant Provides Corporate Update And Reports Financial Results For First Fiscal Quarter Ended June 30, 2017
8/11/2017
-
Myovant Bolsters Executive Team With Key Management Appointments
7/20/2017
-
Myovant Initiates Phase III Clinical Program Of Relugolix In Women With Endometriosis-Associated Pain
6/29/2017
-
Myovant Announces Presentation Of Data At The European Congress Of Endocrinology From Phase ll Extension Study Evaluating Relugolix In Women With Endometriosis-Associated Pain
5/24/2017